Carmoterol

Carmoterol

Systematic (IUPAC) name
8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one
Clinical data
Legal status	Development terminated
Routes of administration	Inhalation
Identifiers
ATC code	None
PubChem	CID: 63952
ChemSpider	57545 Y
UNII	9810NUL4D1 Y
ChEMBL	CHEMBL1094785 Y
Chemical data
Formula	C21H24N2O4
Molecular mass	368.43 g·mol−1
SMILES COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3NC(=O)C=Cc23)cc1
InChI InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1 Key:IHOXNOQMRZISPV-YJYMSZOUSA-N

Carmoterol (INN), also known as TA-2005 and CHF-4226, is a non-catechol experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA) that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg. The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. It is over 100 times more selective for bronchial muscle than myocardial tissue.